Essential thrombocythemia - Open Access .click

Results 101 to 110 of about 3,046,243 (224)

Updates in the management of polycythemia vera and essential thrombocythemia

Therapeutic Advances in Hematology, 2019
Polycythemia vera (PV) and essential thrombocythemia (ET) are both classic, relatively indolent, chronic Philadelphia-chromosome-negative (Ph−) myeloproliferative neoplasms (MPNs) characterized by elevated blood counts, thrombotic as well as hemorrhagic ...
P. Bose, S. Verstovsek
semanticscholar +1 more source

Non ST-segment elevation myocardial infarction in patient with essential thrombocythemia

Thrombosis Journal, 2009
A 68-year-old woman presented with acute chest pain and a greatly increased platelet count. Cardiac catheterization revealed subtotal occlusion and a thrombus-like filling defect in the right coronary artery.
Tengiz Istemihan +8 more
doaj +1 more source

Crosstalk between Oxidative Stress, Chronic Inflammation and Disease Progression in Essential Thrombocythemia

Revista de Chimie, 2019
Essential thrombocythemia (ET) is a Philadelphia-negative chronic myeloproliferative neoplasm characterized by acquired somatic mutations: JAK2, CALR or MPL.
A. Găman, C. Moisă, C. Diaconu, M. Găman +3 more
semanticscholar +1 more source

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia

Cancer Chemotherapy and Pharmacology, 2019
Fedratinib (SAR302503, TG101348) is an orally administered Janus kinase (JAK) 2-selective inhibitor that is being developed for the treatment of patients with myelofibrosis (MF).
K. Ogasawara +4 more
semanticscholar +1 more source

Complex intracranial vascular complications caused by essential thrombocythemia: a critical case report [PDF]